Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer

Mohammad R. Akbari, Laura N. Anderson, Daniel D Buchanan, Mark Clendenning, Mark A. Jenkins, Aung Ko Win, John L. Hopper, Graham G. Giles, Robert Nam, Steven A Narod, Steven Gallinger, Sean P. Cleary

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)


Introduction: The HOXB13 pGly84Glu mutation has recently been associated with an increased risk of prostate cancer but the association of other cancer sites with this allele has not been assessed. Data has suggested that HOXB13 expression levels are decreased in colorectal cancer (CRC) cell lines indicating this gene may be involved in colorectal tumourigenesis. Methods: To evaluate a potential association of this mutation with CRC, we genotyped the mutation in 2695 CRC cases and 4593 controls from population-based registries in Canada and Australia. Results: The HOXB13 pGly84Glu mutation was more common in CRC cases than controls (0.48% vs. 0.17%, P = 0.02) indicating a significant association between the HOXB13 variant and CRC risk (OR = 2.8; 95%CI: 1.2-6.8). This association was attenuated but remained significant with the inclusion of previously published and publicly available genotype data. Pedigree analysis of cases and controls revealed that 7/21 HOXB13 mutation carriers had a family history of prostate cancer. Discussion: This report is the first to suggest a risk of CRC associated with mutations in the HOXB13 gene. These findings require further validation but may be of importance in the screening and genetic counseling of families known to carry the HOXB13 pGly84Glu mutation.

Original languageEnglish
Pages (from-to)424-427
Number of pages4
JournalCancer Epidemiology
Issue number4
Publication statusPublished - Aug 2013
Externally publishedYes


  • Colorectal cancer
  • Genetic polymorphism
  • HOXB13 gene
  • Risk

Cite this